

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited taken no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code : 8189)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice of the EGM of the Company dated 7 September 2026 were duly passed at the EGM of the Company held on 24 September 2026.

RESULTS OF THE EXTRAORDINARY GENERAL MEETING

Reference is made to the notice of the extraordinary general meeting of the Company dated 7 September 2026 (the "Notice"). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Notice. The board of directors (the "Board") of the Company is pleased to announce that all the resolutions as set out in the Notice were duly passed by way of poll at the extraordinary general meeting of the Company held on 24 September 2026.

As at the date of the extraordinary general meeting, the Company had 2,133,900,000 issued Shares, being the total number of Shares entitling the holders thereof to attend and vote on the proposed resolutions at the extraordinary general meeting. No Shareholder had a material interest in any of the matters considered at the extraordinary general meeting and no Shareholder was required under the GEM Listing Rules to abstain from voting on any of the proposed resolutions; no Shareholder had stated in the circular his/her intention to vote against or to abstain from voting on any of the proposed resolutions at the extraordinary general meeting; and no Shares entitled their holders to attend and abstain from voting in favour of any of the proposed resolutions at the extraordinary general meeting as set out in Rule 17.47A of the GEM Listing Rules.

Details of the poll results in respect of the resolutions proposed at the extraordinary general meeting are as follows:

		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
Special Resolution				
1.	THAT, subject to the approval of the shareholders of the Company and the fulfilment of the filing requirements with the Administration for Industry and Commerce, the following clauses be added to the Articles of Association of the Company and the Board be granted a specific authorisation (as defined in the circular) : “The Articles of Association authorise the Board to resolve, within three years, to issue shares not exceeding 50% of the issued shares. However, where capital contribution is made with non-monetary property, a resolution of the shareholders' meeting shall be required. Where the issue of shares resolved by the Board pursuant to the preceding paragraph results in any change to the registered capital or the number of issued shares of the Company, no further vote at a shareholders' meeting shall be required for the amendment of such particulars as recorded in the Articles of Association. Where the Articles of Association authorise the Board to resolve to issue new shares, the resolution of the Board shall be passed by more than two-thirds of all directors. In exercising this authorisation, the Board shall comply with the securities regulatory rules of the place where the shares of the Company are listed.”	482,715,000 shares 72.57%	182,500,000 shares 27.43%	665,215,000 shares

This resolution is only summarised. The full text is set out in the notice of the extraordinary general meeting of the Company.

As more than two-thirds of the votes cast were in favour of the above resolution, it was duly passed as a special resolution at the extraordinary general meeting.

Mr. Yang Zeng, executive Director, Mr. Xia Alan Zhe and Mr. Wang Lei, non-executive Directors, and Mr. Tu Xiangzhen and Mr. Chen Jiang, independent non-executive Directors, attended the extraordinary general meeting.

Peking Certified Public Accountants (中勤萬信會計師事務所), an independent external accountants firm acted as the scrutineer for the purpose of vote-taking at the extraordinary general meeting.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
24 September 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. YangZeng; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing, Mr. Wang Lei and Mr. Xia Alan Zhe; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the Stock Exchange's website at <http://www.hkexnews.hk> on the "Latest Listed Company Information" page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.